ArticleEuropean journal of nuclear medicine and molecular imaging2016
The asphericity of the metabolic tumour volume in NSCLC: correlation with histopathology and molecular markers.
Article in European journal of nuclear medicine and molecular imaging, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 2 syntheses or guidelines pooled it, 62 citations in OpenAlex.
- Augmented expression of Ki-67 is correlated with clinicopathological characteristics and prognosis for lung cancer patients: an up-dated systematic review and meta-analysis with 108 studies and 14,732 patients.Respiratory research · 2018Pooled it
- Standardized Uptake Values Derived fromContrast media & molecular imaging · 2018Pooled it
- MRI features can predict EGFR expression in lower grade gliomas: A voxel-based radiomic analysis.European radiology · 2018Trial
- CONSORT-Independent prognostic value of asphericity of pretherapeutic F-18 FDG uptake by primary tumors in patients with breast cancer.Medicine · 2017Trial
- Radiomics-based gradient boosting model on contrast-enhanced MRI for non-invasive prediction of epidermal growth factor receptor expression and therapeutic response to EGFR-targeted antibody-drug conjugates in high-grade glioma organoid models.Journal of translational medicine · 2026Article
- A narrative review of imaging intratumor heterogeneity in non-small cell lung cancer: current advances.Translational lung cancer research · 2025Review
- Integrative Analysis of Cuproptosis-Related Mitochondrial Depolarisation Genes for Prognostic Prediction in Non-Small Cell Lung Cancer.Journal of cellular and molecular medicine · 2025Article
- Prediction of TP53 mutations across female reproductive system pan-cancers using deep multimodal PET/CT radiogenomics.Frontiers in medicine · 2025Article
- Article
- Promising Candidate Prognostic Biomarkers in [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- An assessment of PET and CMR radiomic features for the detection of cardiac sarcoidosis.Frontiers in nuclear medicine · 2024Article
- Combination of tumor asphericity and an extracellular matrix-related prognostic gene signature in non-small cell lung cancer patients.Scientific reports · 2023Article
- Exploring the efficacy ofAbdominal radiology (New York) · 2023Article
- Value of [Scientific reports · 2023Article
- Asphericity derived from [Scientific reports · 2023Article
- SUVmax to tumor perimeter distance: a robust radiomics prognostic biomarker in resectable non-small cell lung cancer patients.European radiology · 2022Article
- The combined role of PET/CT metabolic parameters and inflammatory markers in detecting extensive disease in small cell lung cancer.Frontiers in oncology · 2022Article
- Exploring the Utility of Radiomic Feature Extraction to Improve the Diagnostic Accuracy of Cardiac Sarcoidosis Using FDG PET.Frontiers in medicine · 2022Article
- Integration of PET/CT Radiomics and Semantic Features for Differentiation between Active Pulmonary Tuberculosis and Lung Cancer.Molecular imaging and biology · 2021Article
- Influencing Factors and Prognostic Value ofInternational journal of general medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAsphericity (ASP) is a tumour shape descriptor based on the PET image. It quantitates the deviation from spherical of the shape of the metabolic tumour volume (MTV). In order to identify its biological correlates, we investigated the relationship between ASP and clinically relevant histopathological and molecular signatures in non-small-cell lung cancer (NSCLC).
methodsThe study included 83 consecutive patients (18 women, aged 66.4 ± 8.9 years) with newly diagnosed NSCLC in whom PET/CT with
resultsSUVmax, MTV and ASP were associated with pathological T stage (Kruskal-Wallis, p = 0.001, p < 0.0005 and p < 0.0005, respectively) and N stage (p = 0.017, p = 0.003 and p = 0.002, respectively). Only ASP was associated with M stage (p = 0.026). SUVmax, MTV and ASP were correlated with Ki-67 index (Spearman's rho = 0.326/p = 0.003, rho = 0.302/p = 0.006 and rho = 0.271/p = 0.015, respectively). The latter correlations were considerably stronger in adenocarcinomas than in squamous cell carcinomas. ASP, but not SUVmax or MTV, showed a tendency for a significant association with the extent of VEGF expression (p = 0.058). In multivariate Cox regression analysis, ASP (p < 0.0005) and the presence of distant metastases (p = 0.023) were significantly associated with progression-free survival. ASP (p = 0.006), the presence of distant metastases (p = 0.010), and Ki-67 index (p = 0.062) were significantly associated with overall survival.
conclusionThe ASP of primary NSCLCs on FDG PET images is associated with tumour dimensions and molecular markers of proliferation and angiogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.